T Fréour1, P Barrière2, D Masson3. 1. Service de médecine et biologie du développement et de la reproduction, Hôpital mère et enfant, CHU de Nantes, 38 boulevard Jean Monnet, 44093 Nantes, France; Faculté de médecine, Université de Nantes, 1 rue Gaston Veil, 44035 Nantes, France; INSERM UMR 1064 - ITUN, CHU de Nantes, 30 boulevard Jean Monnet, 44093 Nantes, France. Electronic address: thomas.freour@chu-nantes.fr. 2. Service de médecine et biologie du développement et de la reproduction, Hôpital mère et enfant, CHU de Nantes, 38 boulevard Jean Monnet, 44093 Nantes, France; Faculté de médecine, Université de Nantes, 1 rue Gaston Veil, 44035 Nantes, France; INSERM UMR 1064 - ITUN, CHU de Nantes, 30 boulevard Jean Monnet, 44093 Nantes, France. 3. Faculté de médecine, Université de Nantes, 1 rue Gaston Veil, 44035 Nantes, France; Laboratoire de biochimie, Institut de biologie, CHU de Nantes, 7 quai Moncousu, 44000 Nantes, France; INSERM UMR 913, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes, France.
Abstract
BACKGROUND: Long-term consequences of cancer treatments in young women, and especially fertility issues, are gaining attention as survival rates increase. Breast cancer is the most frequent malignancy in women of reproductive age. AIM: The purpose of this review is to describe serum anti-müllerian hormone (AMH) level at diagnosis and its evolution during and after chemotherapy in women of reproductive age treated for breast cancer. Second, the impact of taxanes on AMH, the association between AMH and amenorrhea, and the comparison of AMH with other hormonal markers of ovarian reserve were studied. METHODS: A systematic PubMed search was conducted on all articles, published up to April 2016 and related to AMH in women suffering from breast cancer using the following key words: AMH, müllerian-inhibiting substance, ovarian reserve, ovarian function, breast cancer, gonadotoxicity, ovarian toxicity, amenorrhea, chemotherapy, and menopause. RESULTS: AMH levels rapidly fall down to undetectable levels in most women during chemotherapy and generally persist at very low levels in most women after the treatment. Taxanes seem to impact negatively ovarian function, but data on ovarian reserve are scarce. AMH is a predictor of the occurrence of chemotherapy-related amenorrhea and is the most relevant hormonal marker of ovarian reserve. CONCLUSION: Serum AMH is a relevant tool for ovarian reserve assessment and follow-up during treatment in premenopausal women with breast cancer. Further large prospective studies are necessary to determine its predictive interest for post-treatment residual fertility, and eventually use it in fertility preservation counseling before treatment initiation.
BACKGROUND: Long-term consequences of cancer treatments in young women, and especially fertility issues, are gaining attention as survival rates increase. Breast cancer is the most frequent malignancy in women of reproductive age. AIM: The purpose of this review is to describe serum anti-müllerian hormone (AMH) level at diagnosis and its evolution during and after chemotherapy in women of reproductive age treated for breast cancer. Second, the impact of taxanes on AMH, the association between AMH and amenorrhea, and the comparison of AMH with other hormonal markers of ovarian reserve were studied. METHODS: A systematic PubMed search was conducted on all articles, published up to April 2016 and related to AMH in women suffering from breast cancer using the following key words: AMH, müllerian-inhibiting substance, ovarian reserve, ovarian function, breast cancer, gonadotoxicity, ovarian toxicity, amenorrhea, chemotherapy, and menopause. RESULTS:AMH levels rapidly fall down to undetectable levels in most women during chemotherapy and generally persist at very low levels in most women after the treatment. Taxanes seem to impact negatively ovarian function, but data on ovarian reserve are scarce. AMH is a predictor of the occurrence of chemotherapy-related amenorrhea and is the most relevant hormonal marker of ovarian reserve. CONCLUSION: Serum AMH is a relevant tool for ovarian reserve assessment and follow-up during treatment in premenopausal women with breast cancer. Further large prospective studies are necessary to determine its predictive interest for post-treatment residual fertility, and eventually use it in fertility preservation counseling before treatment initiation.
Authors: Rosalba Torrisi; Vera Basilico; Laura Giordano; Michele Caruso; Antonino Musolino; Marta Noemi Monari; Carlo Carnaghi; Armando Santoro Journal: Breast Care (Basel) Date: 2021-03-04 Impact factor: 2.860
Authors: Nikita M Shah; Dana M Scott; Pridvi Kandagatla; Molly B Moravek; Erin F Cobain; Monika L Burness; Jacqueline S Jeruss Journal: Ann Surg Oncol Date: 2019-01-24 Impact factor: 5.344
Authors: Jae Jun Shin; Young Min Choi; Jong Kwan Jun; Kyung-Hun Lee; Tae-Yong Kim; Wonshik Han; Seock-Ah Im Journal: J Breast Cancer Date: 2020-05-11 Impact factor: 3.588
Authors: Valentino Martelli; Maria Maddalena Latocca; Tommaso Ruelle; Marta Perachino; Luca Arecco; Kristi Beshiri; Maria Grazia Razeti; Marco Tagliamento; Maurizio Cosso; Piero Fregatti; Matteo Lambertini Journal: Breast Cancer (Dove Med Press) Date: 2021-05-24